Recognised for its transactional strength, Goodwin is well-placed to advise companies and investors in life sciences and healthcare on financings, investments, M&A and joint ventures. The ‘seamless’ team is jointly led by David Mardle, who advises emerging companies on corporate and capital markets transactions; Graham Defries, who focuses on funding and collaboration transactions for biotech and pharma companies and investors; Sophie McGrath, experienced in a range of corporate matters at all stages of development; and ’highly attentive’ Arvin Abraham, who specialises in PE, VC and strategic investments in medtech, medical devices, digital health and healthcare services. Maria Dragun, promoted to partner in October 2024, is noted for her attention to detail in cross-border transactions. Anna Humphrey joined from Orrick in January 2025, strengthening the team’s employee incentives sector expertise. Hayley Davis is no longer at the firm.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
'Goodwin has a seamless team of corporate lawyers that collaborate on key strategic questions and can seamlessly fill in for each other as needed. No one works as hard or as thoughtfully to support their life science clients.'
'Availability and professionalism.'
‘Extensive specific experience and knowledge of biotech-pharma deals. Provide a comprehensive approach to proactively consider all risks and potential issues while maintaining a pragmatic commercial view. Advice is clear, balanced and helpful and considers all stakeholders involved in a transaction.’
‘Andrew Harrow is extremely knowledgeable, calm, takes full ownership of every aspect of the deal and works with all stakeholders to get transactions to a conclusion. Maria Dragun is very thorough, with excellent attention to detail, meets all deadlines and goes the extra mile to get a deal done, excellent communication and clear answers to questions. ’
‘Arvin Abraham is highly attentive, proactive and accessible.'
'Maria and Andrew are extensions of our senior team. They’re valued thought partners, an invaluable source of legal advice and well-respected by our counterparties. They’re also seamlessly integrated with the US team. I wouldn’t consider working with anyone else.'
Key clients
- Kynos Therapeutics
- Adcendo
- Quanta Dialysis
- Novo Holdings
- Purespring Therapeutics
- TA Associates
- Zealand Pharma
- Vicebio
- Myricx
- Endomagnetics
- Tenpoint Therapeutics
- EQT
Work highlights
Advised Adcendo, a clinical-stage biotechnology company developing breakthrough antibody-drug conjugates for the treatment of underserved cancers, on the closing of an oversubscribed $135 million Series B financing round.
Advised TA Associates on its joint investment with Novo Holdings in Biocomposites, an international medical devices company that engineers, manufactures and markets products for use in infection management in bone and soft tissue.
Advised Zealand on an exclusive collaboration and licensing agreement worth up to USD 5.3 billion with F. Hoffmann-La Roche AG (“Roche”), to co-develop and co-commercialise Zealand’s obesity asset, petrelintide, in the U.S. and Europe.
Lawyers
Hall of Fame
The lawyers at the very top of the profession, widely known and respected by peers and clients for their longstanding involvement in market-leading work.
Practice head
David Mardle; Graham Defries; Sophie McGrath; Arvin Abraham
Other key lawyers
Maria Dragun; Andrew Harrow; Richard Bloomfield; Anna Humphrey